Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Cancer Metastatic × Aromatase Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 39 Arthralgia 3 Advanced Breast Cancer 3 Polycystic Ovary Syndrome 2 Osteoporosis 2 Fractures, Bone 2 Carcinoma, Intraductal, Noninfiltrating 2 Breast Cancer Female 2 Sexuality 1 Neurotoxicity Syndromes 1 Neoplasm Metastasis 1 Luminal B/HER2-negative Breast Cancer 1 Leiomyoma 1 Infertility 1 Hormone-receptor-positive Breast Cancer 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Fatigue 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Endometrial Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Bone Diseases, Metabolic 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Fulvestrant 4 Letrozole 3 ribociclib 2 exemestane 2 dalpiciclib 2 apatinib 2 Anastrozole 2 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1 Cell Separation 1 Capecitabine 1 Bevacizumab 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02511639 2020-12-03

MAIN-A

Istituto Oncologico Veneto IRCCS

Phase 3 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡